Stock listing

gettex:TKD Takeda Pharmaceutical Co. Ltd. Aktie

German listing (gettex) of Takeda Pharmaceutical Co. Ltd. · home listing Tokyo:4502

Follow Takeda Pharmaceutical Co. Ltd. into a list and get an email when it puts out news.

Takeda Pharmaceutical Co. Ltd. logo
Ticker
gettex:TKD
Asset type
Stock
Exchange
gettex
Currency
EUR

What changed lately

Calls

Replays

  • Takeda Pharmaceutical (Tokyo:4502) Q1 2026 Earnings Call

    Thu, Jul 30, 2026 · 6:00 AM ET

    Watch Transcript

  • Takeda Pharmaceutical (Tokyo:4502) Q4 2025 Earnings Call

    Wed, May 13, 2026 · 6:00 AM ET

    Watch Transcript

  • Takeda Pharmaceutical (Tokyo:4502) Q2 2025 Earnings Call

    Thu, Oct 30, 2025 · 6:00 AM ET

    Watch Transcript

Latest news

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Oct 14, 2026

Takeda Pharmaceutical to Hold Earnings Call for Fiscal Year 2026 2nd Quarter on October 29

Oct 14, 2026

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

Sep 22, 2026

Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems

Sep 18, 2026

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations

Sep 14, 2026

Takeda Pharmaceutical Announces Planned Retirement of President of Research & Development Andy Plump

Sep 10, 2026

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life

Sep 9, 2026

Takeda Receives U.S. FDA Approval of MIMRYLO, Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

Aug 31, 2026

Takeda Receives U.S. FDA Approval of MIMRYLO (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

Aug 28, 2026

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Aug 24, 2026

All Takeda Pharmaceutical Co. Ltd. news

Decks

Takeda Pharmaceutical Co. Ltd. on 6ix

News releases
71 in the last 12 months · 97 in all · newest Oct 15, 2026 · oldest 2025
Calls
19 calls with a replay · 19 with a transcript · latest Jul 30, 2026
Decks
87 decks · latest Jul 30, 2026

Where Takeda Pharmaceutical Co. Ltd. is listed

ListingExchangeCountryCurrency
Tokyo:4502 武田薬品工業 · Home listingTokyoJapanJPY
NYSE:TAKNYSEUnited StatesUSD
OTC:TKPHFOTCUnited StatesUSD
SAPSE:4502 武田薬品工業SAPSEJapanJPY
gettex:TKD · This pagegettexGermanyEUR
NAG:4502 武田薬品工業NAGJapanJPY
Tradegate:TKDTradegateGermanyEUR
Frankfurt:TKDFrankfurtGermanyEUR
gettex:TKDAgettexGermanyEUR
LS Exchange:853849LS ExchangeGermanyEUR
LSE:0A87LSEUnited KingdomUSD
Lang & Schwarz:853849Lang & SchwarzGermanyEUR
FSE:4502 武田薬品工業FSEJapanJPY
LSE:0RN3LSEUnited KingdomEUR
BOATS:TAKBOATSUnited StatesUSD
B3:TAKP34B3BrazilBRL
VIE:TKDViennaAustriaEUR
BMV:TAKNBMVMexicoMXN
Dusseldorf:TKDDusseldorfGermanyEUR
Frankfurt:TKDAFrankfurtGermanyEUR
Hamburg:TKDHamburgGermanyEUR
Hanover:TKDHanoverGermanyEUR
Lang & Schwarz:A1CWZFLang & SchwarzGermanyEUR
Munich:TKDMunichGermanyEUR
Tradegate:TKDATradegateGermanyEUR
Dusseldorf:TKDADusseldorfGermanyEUR
Hamburg:TKDAHamburgGermanyEUR
LS Exchange:A1CWZFLS ExchangeGermanyEUR
Munich:TKDAMunichGermanyEUR
Stuttgart:TKDStuttgartGermanyEUR
Stuttgart:TKDAStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Takeda Pharmaceutical Co. Ltd.